Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 2—February 2025
Research
Contribution of Limited Molecular Testing to Low Ehrlichiosis Diagnosis in High Incidence Area, North Carolina, USA
Alexis Siegler, Lauryn Ursery, Dana A. Giandomenico, Melissa B. Miller, Johanna S. Salzer, Alexis M. Barbarin, Carl Williams, and Ross M. Boyce
Table 2
Clinical manifestations and titers of patients confirmed with Ehrlichia sp. infection within the University of North Carolina health system, March 24, 2022–April 14, 2023*
| Category | Patient identification no. |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 548 | 549 | 640 | 765 | 935 | 951 | 1278 | 1337 | 1339 | 1370 | 1466 | 1655 | |
| Serologic testing results |
||||||||||||
| Acute Ehrlichia IgG titer |
>1:64 |
1:128 |
1:128 |
<1:64 |
<1:64 |
>1:64 |
1:128 |
<1:64 |
<1:64 |
1:128 |
<1:64 |
<1:64 |
| Convalescent Ehrlichia IgG titer | 1:256 | 1:1,024 | 1:1,024 | 1:128 | 1:1,024 | 1:1,024 | 1:512 | 1:128 | 1:128 | 1:512 | 1:512 | 1:128 |
*N, no; NA, not available; Y, yes.
Page created: January 13, 2025
Page updated: January 31, 2025
Page reviewed: January 31, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.